cagrilintide amyloid fibrils is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had ≥1 weight-related complication, individuals assigned to a combination New in the August 14,
New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) CagrilintideSemaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Cagrilintide (10mg) Australia Research Grade VRL Cagrilintide Long Acting Amylin Analogue for Research Pepitiva Biolabs Amyloidogenicity of peptides targeting diabetes and obesity ScienceDirect
Pay in 4 interest-free payments of $5.27 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6


